CI Financial Q2 EPS $0.75 Up From $0.57 YoY

CI Financial (NYSE:CIXX) reported quarterly earnings of $0.75 per share. This is a 31.58 percent increase over earnings of $0.57 per share from the same period last year.

byBenzinga Newsdesk

August 10, 2021

1 minute read

CI Financial (NYSE:CIXX) reported quarterly earnings of $0.75 per share. This is a 31.58 percent increase over earnings of $0.57 per share from the same period last year.

AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses

By Vandana Singh

Today, 3:39 AM

AIM ImmunoTech Inc (NYSE:AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal…

AIM

Crexendo Q2 EPS $0.00 Misses $0.01 Estimate, Sales $5.80M Beat $5.56M Estimate

By Benzinga Newsdesk

Today, 3:39 AM

Crexendo (NASDAQ:CXDO) reported quarterly sales of $5.80 million which beat the analyst consensus estimate of $5.56 million by 4.32 percent. This is a 43.07 percent increase over sales of $4.05 million the same period

CXDO

Earnings

PolarityTE Q4 2021 Earnings Conference Call On March 30, 2022 At 08:30 AM ET

By Benzinga Insights

Today, 3:39 AM

PolarityTE (NASDAQ:PTE) will host a conference call at 08:30 AM ET on March 30, 2022, to discuss Q4 2021 earnings results. How to Attend PolarityTE (PTE) Conference Call Follow this link to access the live webcast.

PTE

Credit Suisse Downgrades Aveanna Healthcare Hldgs to Underperform, Lowers Price Target to $1

By Benzinga Newsdesk

Today, 3:39 AM

Credit Suisse analyst A.J. Rice downgrades Aveanna Healthcare Hldgs (NASDAQ:AVAH) from Neutral to Underperform and lowers the price target from $2 to $1.

AVAH

CI Financial Q2 EPS $0.75 Up From $0.57 YoY

Related Posts

AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses

Crexendo Q2 EPS $0.00 Misses $0.01 Estimate, Sales $5.80M Beat $5.56M Estimate

PolarityTE Q4 2021 Earnings Conference Call On March 30, 2022 At 08:30 AM ET

Credit Suisse Downgrades Aveanna Healthcare Hldgs to Underperform, Lowers Price Target to $1